Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry
about
Comparative risk of hospitalized infection between biological agents in rheumatoid arthritis patients: A multicenter retrospective cohort study in Japan.Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted BiologicsTocilizumab in refractory rheumatoid arthritis: long-term efficacy, safety, and tolerability beyond 2 yearsCurrent clinical evidence of tocilizumab for the treatment of ANCA-associated vasculitis: a prospective case series for microscopic polyangiitis in a combination with corticosteroids and literature review.Drug survival and reasons for discontinuation of the first biological disease modifying antirheumatic drugs in Thai patients with rheumatoid arthritis: Analysis from the Thai Rheumatic Disease Prior Authorization registry.An effective medical partnership in Nagasaki, Japan for patients with rheumatoid arthritis.Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study.Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA.Corticosteroid-free treatment of tocilizumab monotherapy for microscopic polyangiitis: a single-arm, single-center, clinical trial.The growth factor midkine may play a pathophysiological role in rheumatoid arthritis.Additional effect of etanercept or infliximab on the liver function tests of patients with rheumatoid arthritis: a cohort study
P2860
Q33778719-45377EB2-45C6-499F-8010-4987C9CD98FCQ33809045-73894888-7929-47C7-A827-58269A7FA82AQ36757435-6359636B-5B9B-4CAA-8013-1689E8A63C64Q38653449-45E8F83F-240C-40F3-B3A5-589768EDF7FBQ38664981-5FA0C414-5880-4F22-BDFA-848846CFE604Q39967995-A143126E-74E6-4B93-8F83-BA3090A75248Q40169531-E1749730-9077-4730-BF94-69A0D5394187Q47861250-303FE520-8EE7-43B6-9AE8-0C2C200AD9D8Q50700806-8E78A9C5-AB9E-4A42-B554-8E14DEB9762BQ52870428-2753C184-DF3B-4BB1-9AB4-9E351D16355AQ57817317-6C6BEE61-3E31-47B4-A9D1-2AE0BAB11065
P2860
Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Head-to-head comparison of the ...... ng-term safety (REAL) registry
@ast
Head-to-head comparison of the ...... ng-term safety (REAL) registry
@en
type
label
Head-to-head comparison of the ...... ng-term safety (REAL) registry
@ast
Head-to-head comparison of the ...... ng-term safety (REAL) registry
@en
prefLabel
Head-to-head comparison of the ...... ng-term safety (REAL) registry
@ast
Head-to-head comparison of the ...... ng-term safety (REAL) registry
@en
P2093
P2860
P1476
Head-to-head comparison of the ...... ng-term safety (REAL) registry
@en
P2093
Atsuhisa Ueda
Hayato Nagasawa
Hayato Yamazaki
Hiroaki Dobashi
Kaori Watanabe
Kazuhiko Ezawa
Kazuyoshi Saito
Kiyoshi Migita
Koichi Amano
Masayoshi Harigai
P2860
P2888
P356
10.1186/S13075-015-0583-8
P577
2015-03-23T00:00:00Z
P5875
P6179
1053674182